Literature DB >> 16029226

A review of an anaesthetic led vascular access list.

S Galloway1, A Sharma, J Ward, A R Bodenham.   

Abstract

The demand for insertion of long-term central venous (Hickman type) catheters is thought to be increasing. Organisation is required to meet this demand in a safe and efficient manner. This report reviews the results from a dedicated, anaesthetic led vascular access list over the initial 61-month period. One thousand procedures were performed. Nine hundred and twenty catheters were inserted under local anaesthesia, with or without intravenous sedation and analgesia. Eighty catheters were removed. All procedures were performed during a dedicated once weekly, morning list. A total of 53% of all procedures were performed on a day-case basis, 43% on in-patients. Only 1.5% of patients required an unexpected overnight stay (usually medically unfit patients). There were 81 (9%) cancellations on the day of procedure due to neutropaenia, pneumonia or urinary tract infections. Ultrasound guidance was used initially selectively in 14%, latterly in 100% of procedures and fluoroscopy in all insertions to confirm or adjust catheter position. This service has been well received by patients and oncology services. In addition it provides an interesting area of practice for anaesthetists and an ideal environment for teaching more advanced aspects of central venous access. It may provide a template of service for other centres.

Entities:  

Mesh:

Year:  2005        PMID: 16029226     DOI: 10.1111/j.1365-2044.2005.04189.x

Source DB:  PubMed          Journal:  Anaesthesia        ISSN: 0003-2409            Impact factor:   6.955


  1 in total

1.  Peripherally inserted central venous catheters and central venous catheters related thrombosis in post-critical patients.

Authors:  Manuela Bonizzoli; Stefano Batacchi; Giovanni Cianchi; Giovanni Zagli; Francesco Lapi; Valentina Tucci; Giacomo Martini; Simona Di Valvasone; Adriano Peris
Journal:  Intensive Care Med       Date:  2010-09-21       Impact factor: 17.440

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.